Childhood-onset scleroderma: Is it different from adult-onset disease?

Arthritis and Rheumatism

Volumn 39, Issue 6, 1996, Pages 1041-1049

  Vancheeswaran, Rama ^a   Black, Carol M ^a   David, Joel ^b   Hasson, Nathan ^c   Harper, John ^d   Atherton, David ^d   Trivedi, Premila ^e   Woo, Patricia ^f  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Battle Hospital   (United Kingdom)

^c EALING HOSPITAL   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; INTERLEUKIN 2 RECEPTOR; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD INJURY; CLINICAL FEATURE; COLLAGEN SYNTHESIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHEA; ONSET AGE; PRIORITY JOURNAL; SCLERODERMA; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGE OF ONSET; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLLAGEN; FEMALE; HUMANS; MALE; PARTIAL THROMBOPLASTIN TIME; PENICILLAMINE; PLATELET COUNT; PREDNISOLONE; SCLERODERMA, SYSTEMIC; WOUNDS AND INJURIES;

EID: 0029905420     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390624     Document Type: Article

References (58)

1. Tuffanelli DL, Winkelmann RK: Systemic scleroderma: a clinical study of 727 cases. Arch Dermatol 84:359-371, 1961
2. Medsger TA, Masi AT: Epidemiology of systemic sclerosis. Ann Intern Med 74:714-719, 1971
3. Barnet AJ: Epidemiology of systemic sclerosis in Australia. In, Systemic Sclerosis (Scleroderma). Edited by CM Black, AR Myers. New York, Gower Medical, 1985
4. Arboe-Hansen G: Epidemiology of progressive systemic sclerosis in Denmark. In, Systemic Sclerosis (Scleroderma). Edited by CM Black, AR Myers. New York, Gower Medical, 1985
5. Black CM: Prognosis and management of scleroderma and scleroderma-like disorders in children. Clin Exp Rheumatol 12:S75-S81, 1994
6. Black CM: Juvenile scleroderma. In, Pediatric Rheumatology Update. Edited by P Woo, PH White, BM Ansell. New York, Oxford University Press, 1990
7. Hochberg MC, Lopez-Acuna D, Gittelsohn AM: Mortality from systemic sclerosis (scleroderma) in the United States, 1969-1977. In, Systemic Sclerosis (Scleroderma). Edited by CM Black, AR Myers. New York, Gower Medical, 1985
8. Schlesinger M, Schaller JG: Progressive systemic sclerosis (PSS) of childhood (abstract). Arthritis Rheum 24 (suppl 4):S104, 1981
9. Cassidy JT, Petty RE: The sclerodermas and related disorders. In, Textbook of Pediatric Rheumatology. Edited by JT Cassidy, RE Petty. New York, Churchill Livingstone, 1991)
10. Kass H, Hanson V, Patrick J: Scleroderma in childhood. J Pediatr 68:243-256, 1966
11. Liu P, Uziel Y, Chuang S, E. S, Krafchik B, Laxer R: Localized scleroderma-imaging features. Pediatr Radiol 24:207-209, 1994
12. Ansell BM, Falcini F, Woo P: Scleroderma in childhood. Clin Dermatol 12:299-307, 1994
13. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590, 1980
14. Trivedi P, Risteli J, Risteli L, Hindmarsh PC, Brook CGD, Mowat AP: Serum concentrations of the type I and III procollagen peptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Pediatr Res 30:276-280, 1991
15. Trivedi P, Hindmarsh P, Risteli J, Risteli L, Mowat AP, Brook CGD: Growth velocity, growth hormone therapy, serum concentrations of the amino-terminal propeptide of type III procollagen. J Pediatr 114:225-230, 1989
16. Antinuclear Antibodies: Contemporary Techniques and Clinical Applications to Connective Tissue Diseases. New York, Oxford University Press, 1984
17. Bunn C, Kveder T: Immuno-electrophoresis. In, Auto-Antibody Manual. Edited by RN Maini, WJ van Ven-Rooij. Amsterdam, Kluwer Academic Publishers, 1994
18. Thompson RA: Techniques in Clinical Immunology. London, Blackwell Scientific Publications, 1977
19. Thomson J: Blood Coagulation and Haemostasis. Edinburgh, Churchill Livingstone, 1980
20. Holmquist B, Bunning P, Riordan JF: A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem 95:540-545, 1979
21. Gordon JL, Pottinger BE, Woo P, Rosenbaum J, Black CM: Plasma von Willebrand factor in connective tissue disease. Ann Rheum Dis 46:491-492, 1987
22. Mason JC, Kapahi P, Haskard DO: Detection of increased levels of circulating intercellular adhesion molecule I in some patients with rheumatoid arthritis hut not in patients with systemic lupus erythematosus: lack of correlation with levels of circulating vascular cell adhesion molecule I. Arthritis Rheum. 36:519-527, 1993
23. Vancheeswaran R, Magoulas T, Efrat G, Penny RM, Black CM: Circulating endothelin-1 levels in systemic sclerosis (SSc) subsets: a marker of fibrosis or vascular dysfunction? J Rheumatol 21: 1838-1844, 1994
24. Rothfield NF: Autoantibodies in scleroderma. In, Antinuclcar Antibodies, 1992. Edited by DS Pisetsky. Philadelphia, Harcourt Brace Jovanovitch, 483-499, 1992
25. Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W: Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 20:809-814, 1993
26. Gruschwitz MS, Hornstein OP, van den Driesch P: Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 38:184-189, 1995
27. Kahaleh MB: Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Arthritis Rheum 34:978-983, 1991
28. Yamane K, Kashiwagi H, Suzuki N, Miyauchi T, Yanagisawa M, Goto K, Masaki T: Elevated plasma levels of endothelin-1 in systemic sclerosis (letter). Arthritis Rheum 34:243-244, 1991
29. Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H, Kashiwagi H: Significance of plasma endothelin-1 levels in patients with SSc. J Rheumatol 19:1566-1571, 1992
30. LeRoy EC, Black CM, Fleishmajer R, Jahlonska S, Krieg T, Medsger T, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, sunsets and pathogenesis. J Rheumatol 15:202-205, 1988
31. Abere E, Naumann R, Stanek G: Is localized scleroderma a Borrclia infection? Lancet 1:1490, 1985
32. Izguerdo M, Natei I, Rodrigo M, Mener C, Sebastian M, Conde J, Gomez Reino JJ: Chronic juvenile toxic epidemic syndrome. Ann Rheum Dis 44:109-112, 1985
33. Van Vloten WA, Scheffer E, Dooren LJ: Localised scleroderma-like lesions after bone marrow transplantation in man: a chronic graft versus host reaction. Br J Dermatol 97:337-341, 1977
34. Falanga V, Medsger TA, Reichlin M, Rodnan GP: Linear scleroderma: clinical spectrum, prognosis and laboratory abnormalities. Ann Intern Med 104:849-857, 1986
35. Kanzler MH, Gorsulowsky DC, Swanson NA: Basic mechanisms in the healing cutaneous wound. J Dermatol Surg Oncol 12:1156-1164, 1986
36. Macmura K, Kurihara H, Morita T, Oh-hashi Y, Yazaki Y: Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology 38: 29-35, 1992
37. Inoue H, Imokawa H, Yamanaka M, Isono E, Ando K, Kuhota T, Aihara M, Ishida H: Detection of endothelin 1.2 and endothelin-like immunoreactant in wound surface and plasma in mice with thermal injury. Life Sciences 52:PL291-296, 1993
38. Seth S, Sequiera W: Sparing effect of hemiplegia on scleroderma. Ann Rheum Dis 49:999-1000, 1990
39. Black CM: The etiopathogenesis of systemic sclerosis. J Intern Med 234:3-8, 1993
40. Uziel Y, Krafchik BR, Silverman ED, Thorner PS, Laxer RM: Localized scleroderma in childhood: a report of 30 cases. Semin Arthritis Rheum 23:328-340, 1994
41. Woolf AD, Wakerly G, Wallington TB, Scott DGI, Dieppe PA: Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis 46:441-447, 1987
42. Blann AD, Illingworth K, Jayson MIV: Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 20:1325-1330, 1993
43. Matucci-Ccrenic M, Pignone A, Lotti T, Spillantini G, Currdi C, Leoncini G, Iannone F, Falcini F, Cagnoni M: Reduced angiotensin converting enzyme plasma activity in scleroderma: a marker of endothelial injury? J Rheumatol 17:328-330, 1990
44. Matucci-Cerenic M, Pignone A, Iannone F, Lotti T, Pesciulesi E, Spillantini G, Falcini F, Cagnoni M: Clinical correlations of plasma angiotensin converting enzyme (ACE) activity in systemic sclerosis: a longitudinal study of plasma ACE level, endothelial injury and lung involvement. Respir Med 84:283-287, 1990
45. Reimer G: Antibodies against cellular antigens in systemic sclerosis. Rheum Dis Clin North Am 16:169-183, 1990
46. Takehara K, Moroi Y, Nakabayashi Y, Ishibashi Y: Antinuclear antibodies in localized scleroderma. Arthritis Rheum 26:612-616, 1983
47. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K Jr: Soluble interleukin-2 receptors in patients with systemic sclerosis. Arthritis Rheum 33:375-380, 1990
48. Kahaleh MB, Yin TG: Enhanced expression of high-affinity interleukin-2 receptors in scleroderma: possible role for IL-6. Clin Immunol Immunopathol 62:97-102, 1992
49. Uziel Y, Krafchik BR, Feldman B, Silverman ED, Rubin LA, Laxer RM: Serum levels of soluble interleukin-2 receptor: a marker of disease activity in localized scleroderma. Arthritis Rheum 34:898-901, 1994
50. Zachariae H, Halkier-Sorensen L, Heickendorff L: Serum amino-terminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma. Acta Derm Venereol (Stockholm) 69:66-70, 1989
51. Horslav-Peterson K, Ammitzboll T, Engstrom-Laurent A, Bentsen K, Junker P, Asboe-Hansen G, Lorenzen I: Serum and urinary aminoterminal type III procollagen peptide in progressive systemic sclerosis: relationship to sclerodermal involvement, serum hyaluronan and urinary collagen metabolites. J Rheumatol 15:460-467, 1988
52. Black CM, McWhirter A, Harrison NK, Kirk JME, Laurent GJ: Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol 28:98-103, 1989
53. Scheja A, Akesson A, Horslav-Peterson K: Serum levels of amino-terminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis. Scand J Rheumatol 21:5-9, 1991
54. Scheja A, Hellmer G, Wollheim FA, Akesson A: Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease. Br J Rheumatol 32:59-62, 1993
55. Uitto J, Bauer EA, Eisen AZ: Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture. J Clin Invest 64:921-930, 1979
56. Scharfetter K, Buttgeret BL, Krieg T: Localization of collagen mRNA in normal and scleroderma skin by in situ hybridization. Eur J Clin Invest 18:9-17, 1988
57. Kikuchi K, Sato S, Kadono T, Ihn H, Takehara K: Serum concentration of procollagen type I carboxy-terminal propeptide in localized scleroderma. Arch Dermatol 130:1269-1272, 1994
58. Smedsrod B, Melkko J, Risteli L, Risteli J: Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271:345-350, 1990